COLUMBIA, Maryland, July 12. 10, 2022 (GLOBE NEWSWIRE) — WR Grace & Co., a global leader in specialty silica and fine chemicals, today announced it is expanding its contract development and manufacturing facility (CDMO) in South Havre, MI.
The expansion will bring a new 4,000-gallon multipurpose reactor train made of glass-lined construction materials and stainless steel. The extension will also include a HASTELLOY® centrifuge to facilitate product isolation, which greatly enhances the site’s cGMP compliant business capability.
The project will bring South Haven up to three 4,000-gallon general purpose reactor trains enabling Grace’s Fine Chemical Manufacturing Services (FCMS) business to support the continued growth of its small molecule drug production, including custom active pharmaceutical ingredients (APIs), cGMP intermediates and generic APIs. The project is expected to be completed in January 2024.
In June 2021, Grace acquired Albemarle’s FCMS business as part of an expansion to support its pharmaceutical portfolio. The acquisition enabled Grace’s Materials Technologies division to triple its fine chemical footprint while leveraging its existing chromatography resins and formulation excipients in the healthcare and life science markets.
“Our company’s growth strategy is aligned to support the success of our customers,” said Bob Patel, President and CEO of Grace. “Our expansion to South Haven demonstrates this commitment and addresses the growing market demand for small molecule drug manufacturing that has occurred year over year over the past decade. Anticipation of market needs, coupled with our expertise, are key Grace capabilities that work together to enable customer success.
“The FCMS business has a promising growth trajectory as the leading CDMO in North America,” said Sandra Wisniewski, president, Grace Materials Technologies. “The additional capacity created through this project will enable our customers to develop essential drug therapies in areas such as oncology, diabetes, cardiovascular disease and antivirals.”
Grace’s FCMS is a premier North American CDMO offering extensive capabilities for the pharmaceutical, nutraceutical and fine chemical industries. Its network of three fully integrated sites provides an industry-leading flexible supply chain through the upstream integration of its intermediaries.
HASTELLOY® is a registered trademark in the United States and/or other countries of Haynes International, Inc. This release is an independent publication and is not affiliated with, nor has it been authorized, sponsored or otherwise endorsed by the companies aforementioned.
Built on talent, technology and trust, Grace, a Standard Industries company, is one of the world’s leading suppliers of catalysts, engineered materials and fine chemicals. The company’s two leading business segments, Catalysts Technologies and Materials Technologies, provide innovative products, technologies and services that improve the products and processes of our customers worldwide. With approximately 4,300 employees, Grace operates and/or sells to customers in over 60 countries. More information about Grace is available at grace.com.
This announcement contains forward-looking statements, that is, information relating to future and not past events. Such statements generally include the words “believes”, “plans”, “intends”, “will”, “expects”, “prospects” or similar expressions. Forward-looking statements include, but are not limited to: expected financial positions; operating results; cash flow; financing plans; business strategy; operating plans; capital and other expenditures; competitive positions; growth opportunities; benefits from new technologies and cost reduction initiatives; and securities markets. Like other businesses, Grace is subject to risks and uncertainties that could cause its actual results to differ materially from its projections or that could render other forward-looking statements incorrect. Factors that could cause such differences include, but are not limited to: risks associated with overseas operations, particularly in emerging regions; changes in exchange rates; public health and safety issues, including pandemics and quarantines; natural disasters and force majeure; changes in laws and regulations; inflation and availability of raw material, energy and logistics costs; the effectiveness of its investments in research and development and growth; acquisitions and disposals of assets and businesses; developments affecting his pension obligations; legacy matters (including product, environmental and other liabilities) related to Grace’s past business; its legal and environmental proceedings; costs of compliance with environmental laws and regulations (including those relating to climate change); cyber attacks; the economics of its clients’ industries; and changing consumer preferences. Past results should not be taken as an indication of future performance. Readers are cautioned not to place undue reliance on Grace’s projections and forward-looking statements, which speak only as of the date thereof. Grace undertakes no obligation to publicly post any revisions to the projections and forward-looking statements contained in this announcement on this website or to update them to reflect events or circumstances after the date of their posting here.
J +1 412.953.7851